** U.S.-listed shares of Israel-based drug developer PolyPid PYPD.O rise 28.1% to $4.17 premarket
** Co says its experimental treatment to prevent surgical site infection in patients undergoing abdominal colorectal surgery met main goal of late-stage trial
** Treatment called D-PLEX100 is administered along with standard of care treatment to provide prolonged anti-bacterial activity directly at surgical site to prevent infections
** Co says treatment showed 58% reduction in rate of surgical site infections in patients treated with D-PLEX100 vs standard of care
** Co expects to submit marketing application to U.S. FDA in early 2026
** Up to last close, stock up 7.6% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。